These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 31629010)
1. Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential. Higgins GA; Fletcher PJ; Shanahan WR Pharmacol Ther; 2020 Jan; 205():107417. PubMed ID: 31629010 [TBL] [Abstract][Full Text] [Related]
2. The safety and efficacy of lorcaserin in the management of obesity. Hess R; Cross LB Postgrad Med; 2013 Nov; 125(6):62-72. PubMed ID: 24200762 [TBL] [Abstract][Full Text] [Related]
4. Lorcaserin and CP-809101 reduce motor impulsivity and reinstatement of food seeking behavior in male rats: Implications for understanding the anti-obesity property of 5-HT2C receptor agonists. Higgins GA; Silenieks LB; Altherr EB; MacMillan C; Fletcher PJ; Pratt WE Psychopharmacology (Berl); 2016 Jul; 233(14):2841-56. PubMed ID: 27241709 [TBL] [Abstract][Full Text] [Related]
5. Lorcaserin: an investigational serotonin 2C agonist for weight loss. Hurren KM; Berlie HD Am J Health Syst Pharm; 2011 Nov; 68(21):2029-37. PubMed ID: 22011982 [TBL] [Abstract][Full Text] [Related]
6. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity. Nigro SC; Luon D; Baker WL Curr Med Res Opin; 2013 Jul; 29(7):839-48. PubMed ID: 23574263 [TBL] [Abstract][Full Text] [Related]
7. Role of impulsivity and reward in the anti-obesity actions of 5-HT Higgins GA; Zeeb FD; Fletcher PJ J Psychopharmacol; 2017 Nov; 31(11):1403-1418. PubMed ID: 29072522 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of lorcaserin in obesity: a systematic review and meta-analysis of randomized controlled trials. Singh AK; Singh R Expert Rev Clin Pharmacol; 2020 Feb; 13(2):183-190. PubMed ID: 31815555 [No Abstract] [Full Text] [Related]
10. Safety and tolerability review of lorcaserin in clinical trials. Greenway FL; Shanahan W; Fain R; Ma T; Rubino D Clin Obes; 2016 Oct; 6(5):285-95. PubMed ID: 27627785 [TBL] [Abstract][Full Text] [Related]
11. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. Fidler MC; Sanchez M; Raether B; Weissman NJ; Smith SR; Shanahan WR; Anderson CM; J Clin Endocrinol Metab; 2011 Oct; 96(10):3067-77. PubMed ID: 21795446 [TBL] [Abstract][Full Text] [Related]
13. Lorcaserin Hcl for the treatment of obesity. Shukla AP; Kumar RB; Aronne LJ Expert Opin Pharmacother; 2015; 16(16):2531-8. PubMed ID: 26472579 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of chemically diverse 5-HT₂c receptor agonists on behaviours motivated by food and nicotine and on side effect profiles. Higgins GA; Silenieks LB; Lau W; de Lannoy IA; Lee DK; Izhakova J; Coen K; Le AD; Fletcher PJ Psychopharmacology (Berl); 2013 Apr; 226(3):475-90. PubMed ID: 23184281 [TBL] [Abstract][Full Text] [Related]
15. Directly Observable Behavioral Effects of Lorcaserin in Rats. Serafine KM; Rice KC; France CP J Pharmacol Exp Ther; 2015 Dec; 355(3):381-5. PubMed ID: 26384326 [TBL] [Abstract][Full Text] [Related]
16. Effects of 5-HT Higgins GA; Brown M; St John J; MacMillan C; Silenieks LB; Thevarkunnel S Neuropharmacology; 2020 Jun; 170():108064. PubMed ID: 32222404 [TBL] [Abstract][Full Text] [Related]
17. The serotonin-2C agonist Lorcaserin delays intravenous choice and modifies the subjective and cardiovascular effects of cocaine: A randomized, controlled human laboratory study. Pirtle JL; Hickman MD; Boinpelly VC; Surineni K; Thakur HK; Grasing KW Pharmacol Biochem Behav; 2019 May; 180():52-59. PubMed ID: 30811963 [TBL] [Abstract][Full Text] [Related]
18. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. Thomsen WJ; Grottick AJ; Menzaghi F; Reyes-Saldana H; Espitia S; Yuskin D; Whelan K; Martin M; Morgan M; Chen W; Al-Shamma H; Smith B; Chalmers D; Behan D J Pharmacol Exp Ther; 2008 May; 325(2):577-87. PubMed ID: 18252809 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity. Hurren KM; Dunham MW Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):891-896. PubMed ID: 28636828 [TBL] [Abstract][Full Text] [Related]
20. Preclinical evidence for combining the 5-HT Fletcher PJ; Li Z; Silenieks LB; MacMillan C; DeLannoy I; Higgins GA Addict Biol; 2019 May; 24(3):376-387. PubMed ID: 29498158 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]